Insider Trading

NAMSW Stock   11.29  0.88  8.45%   
Slightly above 55% of NewAmsterdam Pharma's sophisticated investors are presently thinking to get in. The analysis of the overall investor sentiment regarding NewAmsterdam Pharma suggests that some traders are interested. NewAmsterdam Pharma's investing sentiment can be driven by a variety of factors including economic data, NewAmsterdam Pharma's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by NewAmsterdam Pharma Executive. Insider Public Trading

Read at macroaxis.com
NewAmsterdam insider trading alert for general transaction of by Lewis William, Executive, on 14th of September 2024. This event was filed by NewAmsterdam Pharma with SEC on 2024-01-04. Initial filing of beneficial ownership - SEC Form 3

Cash Flow Correlation

NewAmsterdam Pharma's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the NewAmsterdam Pharma's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

NewAmsterdam Pharma Fundamental Analysis

We analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Equity

Return On Equity Comparative Analysis

NewAmsterdam Pharma is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

NewAmsterdam Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NewAmsterdam Pharma stock to make a market-neutral strategy. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics with similar companies.

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.